Liquid Array Protein Assay Platform

描述（由申请人提供）：本项目的目的是开发和优化我们的新的基于颗粒的微阵列平台，ArrayableESP，应用于人类血清样品的高多重（50- 2000-plex）蛋白质组学分析。ESP是光学编码的微制造颗粒，可以使用磁力进行操纵。它们是在市售的半导体设备上制造的，使用的是从半导体行业借鉴来的高效和可靠的技术。与现有的基于珠的液体阵列平台相比，它们在成本吞吐量、可扩展性和灵活性方面具有显著优势。我们将在我们的平台上使用适体而不是抗体，这将消除对样品预标记/预处理的需要，并允许在蛋白质结合后进行同质检测的平行方法。ArrayableESP平台与适体的结合有望提高分析的准确性，并简化工作流程。这些属性与ArrayableESP平台提供的几乎无限的多重潜力相结合，将提供一种多重产品，该产品与目前可用的蛋白质组学分析技术相比具有显着优势。ESP技术具有广泛的适用性，并且应该是诊断、预后和表征各种疾病状态（包括癌症、心脏病、关节炎和炎性疾病、肾病、肝病、过敏反应和传染病（例如HIV））的有价值的工具。 公共卫生相关性：其他人已经实现了高效的高度多重基因组分析。蛋白质组分析有望成为改善人类健康的生物学分析的下一个重要组成部分。目前用于多重蛋白质组学分析的方法要么不能进行大于30重的分析，要么在高度多重时需要导致分析不准确且工作流程效率低下的过程。我们正在开发一种具有成本效益的技术，用于低到高的多重蛋白质组学分析，与目前的可比技术相比具有显着优势。该技术应可用于诊断和预后各种疾病状态，包括癌症、心脏病、关节炎和炎性疾病、肾病和传染病（例如HIV）。

DESCRIPTION (provided by applicant): The aim of this project is to develop and optimize our novel particle-based microarray platform, ArrayableESP, for application to high multiplex (50- to 2000-plex) proteomic analysis of human serum samples. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. They are manufactured on commercially available photolithographic equipment using efficient and robust techniques borrowed from the semi-conductor industry. They have significant advantages in cost throughput, scalability, and flexibility over existing bead-based liquid array platforms. We will use aptamers, instead of antibodies, on our platform, which will eliminate the need for sample pre-labeling/pre-processing and allow for a parallel method of homogeneous detection following protein binding. The combination of the ArrayableESP platform with aptamers is expected to increase accuracy of analysis and result in a simplified workflow. Such attributes, in combination with the nearly unlimited multiplex potential offered by the ArrayableESP platform, will provide a multiplex product with significant advantages over currently available technologies for proteomic analysis. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: Efficient high multiplexed genomic analysis has been achieved by others. Analysis of the proteome is expected to be the next important component of biological analysis for improving human health. Current methods for multiplex proteomic analysis are either unable to perform greater than 30-plex analysis, or at high multiplex require processes that result in inaccurate analysis with inefficient workflows. We are developing a cost-effective technology for low to high multiplex proteomic analysis with significant advantages over current comparable technologies. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV).